UK Companies House feature
ATNAHS PHARMA UK LIMITED
Profile
- Company number
- 08789556
- Status
- Active
- Incorporation
- 2013-11-25
- Last accounts made up
- 2025-03-31
- Account category
- GROUP
- Primary SIC
- 21100
- Hubs
- UK Healthcare
Accounts
Pending extraction
No iXBRL extracted yet for this company.
Audit & accounting basis
From AI-extracted PDF accounts
- Accounting basis
- IFRS
- Reporting scope
- Consolidated (group)
- Auditor
- Deloitte LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The Directors believe that overall, the Pharmanovia Holdco Group, which is the largest and smallest Group of undertakings to consolidate these financial statements, is well placed to manage its business risks successfully, and future forecasts show sufficient headroom that has led to the conclusion that adopting the going concern basis of accounting is appropriate.”
Subsidiaries
- Marlborough Pharmaceutical Limited · 100% held · UK
- Atnahs Pharma US Limited · 100% held · UK
- Bone Guardian Limited · 100% held · UK
- Atnahs Pharma Australia Pty Limited · 100% held · Australia
- Pharmanovia A/S · 100% held · Denmark
- Atnahs Pharma Denmark ApS · 100% held · Denmark
- Pharmanovia India Private Limited · 100% held · India
- Pharmanovia Italy S.R.L · 100% held · Italy
- Atnahs Pharma Switzerland AG · 100% held · Switzerland
- Pharmanovia APAC PTE Ltd · 100% held · Singapore
- Pharmanovia Korea Limited · 100% held · Korea
- Pharmanovia Belgium B.V · 100% held · Belgium
- Pharmanovia (Shanghai) pharmaceutical consulting Co,. Ltd · 100% held · China
- Pharmanovia España, S.L. · 100% held · Spain
- Atnahs Pharma France · 100% held · France
- Pharmanovia Pharmanovia GmbH · 100% held · Germany
- Pharmanovia Benelux B.V · 100% held · Netherlands
- Atnahs Pharma Netherlands B.V · 100% held · Netherlands
Significant events
- “During the financial year ending 31 March 2025, the Group encountered a number of operational and financial challenges, including: Regulatory and operational challenges in China which led to higher-than-expected in-market inventory, suppressing primary and secondary sales; Supply challenges in Mexico, which disrupted primary sales; Reduced demand in several markets including Italy and Spain where inventory already in the channel was utilised to meet the lower demand of primary and secondary sales reducing working capital in these markets. These factors impacted the Group's performance for the year ended 31 March 2025 and required management to implement responsive measures to mitigate their effects. The group has embarked on a transformation program which includes a change of executive leadership positions, right sizing the organisation for the new outlook and optimising its commercial and M&A investments given the significant impairments recognised in the current financial year.”
- “On 1 August 2025, the Company sold the licenses related to its Greater China Osteoporosis business to Bone Guardian Limited, a subsidiary undertaking for €54,205k in consideration of share capital in the Bone Guardian Limited Business. No gain or loss was made on the sale of the intangible assets.”
- “On 1 August 2025, the Company sold the share capital of Pharmanovia (Shanghai) pharmaceutical consulting Co,. Ltd to Bone Guardian Limited for €2,328k. No gain or loss was made on the sale of the company.”
- “As at 31 July 25, the Company had drawn down a net balance of €49,390k from its revolving credit facility with Pharmanovia Bidco Limited.”
Auditor / going-concern / subsidiary information is extracted from the PDF version of the latest annual accounts and is not tagged in iXBRL. About these numbers
People
4 active · 13 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| EDER, Stephan, Dr | Director | 2025-10-10 | Jul 1975 | Austrian |
| OMAR, Shiraz Shamshudin | Director | 2026-04-15 | May 1969 | British |
| OWEN, James Mark | Director | 2025-10-10 | Mar 1982 | British |
| WILLIAMS, Neeshe | Director | 2019-08-07 | Feb 1981 | British |
Show 13 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| VISTRA COMPANY SECRETARIES LIMITED | Corporate Secretary | 2016-05-23 | 2023-09-29 |
| BURT, James Charles | Director | 2021-12-07 | 2025-04-01 |
| COTTERILL, Mark John | Director | 2013-11-25 | 2019-08-07 |
| FLOREZ, Felipe | Director | 2021-06-01 | 2023-05-22 |
| HAY, Alastair Thomas Badgett | Director | 2019-08-07 | 2021-12-07 |
| JAVEED, Zubair | Director | 2025-04-01 | 2025-10-10 |
| PATEL, Amit Vijaykumar | Director | 2019-08-07 | 2026-03-19 |
| PATEL, Amit Vijaykumar | Director | 2013-11-25 | 2019-08-07 |
| PATEL, Bhikhu Chhotabhai | Director | 2013-11-25 | 2019-08-07 |
| PATEL, Dipen Vijaykumar | Director | 2013-11-25 | 2019-08-07 |
| PATEL, Rishi Bhikhu | Director | 2019-08-07 | 2022-06-30 |
| PATEL, Santsagar | Director | 2024-06-17 | 2026-01-20 |
| PATEL, Vijay Kumar Chhotabhai | Director | 2013-11-25 | 2019-08-07 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Pharmanovia Bidco Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2019-11-04 | Active |
| Mr Vijay Kumar Chhotabhai Patel | Individual | Shares 50–75%, Voting 25–50% | 2016-04-06 | Ceased 2019-11-04 |
Filing timeline
Last 20 of 115 total filings
| Date | Type | Category | Description |
|---|---|---|---|
| 2026-04-30 | AP01 | officers | appoint person director company with name date |
| 2026-03-20 | TM01 | officers | termination director company with name termination date |
| 2026-03-09 | RP01AP01 | officers | replacement filing of director appointment with name |
| 2026-02-13 | TM01 | officers | termination director company with name termination date |
| 2026-01-29 | CH01 | officers | change person director company with change date |
| 2026-01-05 | AA | accounts | accounts with accounts type group |
| 2025-11-05 | CS01 | confirmation-statement | confirmation statement with updates |
| 2025-10-28 | AP01 | officers | appoint person director company with name date |
| 2025-10-27 | AP01 | officers | appoint person director company with name date |
| 2025-10-16 | TM01 | officers | termination director company with name termination date |
| 2025-06-16 | CH01 | officers | change person director company with change date |
| 2025-06-16 | CH01 | officers | change person director company with change date |
| 2025-05-01 | TM01 | officers | termination director company with name termination date |
| 2025-05-01 | AP01 | officers | appoint person director company with name date |
| 2024-11-29 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2024-11-14 | AA | accounts | accounts with accounts type group |
| 2024-07-05 | MR01 | mortgage | mortgage create with deed with charge number charge creation date |
| 2024-06-21 | CH01 | officers | change person director company with change date |
| 2024-06-19 | AP01 | officers | appoint person director company with name date |
| 2024-04-05 | CH01 | officers | change person director company with change date |
Credit score
Altman Z″ — composite of working capital, retained earnings, EBIT, and leverage
Credit score requires extracted accounts data.
Activity Score
Filings velocity, capital events, officer churn, accounts trajectory
Activity Score not yet computed for this company.